Barclays PLC Has $39,000 Holdings in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Barclays PLC lifted its position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) by 310.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,972 shares of the company’s stock after buying an additional 14,354 shares during the quarter. Barclays PLC owned about 0.07% of Aerovate Therapeutics worth $39,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in AVTE. Bank of New York Mellon Corp grew its stake in shares of Aerovate Therapeutics by 69.9% in the second quarter. Bank of New York Mellon Corp now owns 46,988 shares of the company’s stock valued at $78,000 after buying an additional 19,324 shares in the last quarter. Quest Partners LLC grew its stake in shares of Aerovate Therapeutics by 610.2% in the second quarter. Quest Partners LLC now owns 32,856 shares of the company’s stock valued at $55,000 after buying an additional 28,230 shares in the last quarter. Warberg Asset Management LLC bought a new position in shares of Aerovate Therapeutics in the second quarter valued at $111,000. XTX Topco Ltd bought a new position in Aerovate Therapeutics during the second quarter worth $35,000. Finally, Cubist Systematic Strategies LLC bought a new position in Aerovate Therapeutics during the second quarter worth $53,000.

Aerovate Therapeutics Price Performance

AVTE stock opened at $2.55 on Friday. The company has a fifty day moving average price of $2.63 and a two-hundred day moving average price of $2.17. Aerovate Therapeutics, Inc. has a one year low of $1.25 and a one year high of $32.42. The stock has a market cap of $73.63 million, a price-to-earnings ratio of -0.85 and a beta of 1.00.

Aerovate Therapeutics (NASDAQ:AVTE) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.03. Research analysts anticipate that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.